ADRIATIC Trial Shows Durvalumab as Promising Treatment for Small Cell Lung Cancer

Dr. Julie Gralow presents interim results of the ADRIATIC trial at the 2024 Plenary Session, focusing on durvalumab as a consolidation treatment for limited-stage small cell lung cancer. Results show significant improvements in overall survival and progression-free survival compared to standard care, potentially changing clinical practice in this field.